Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Martin Pomper
Johns Hopkins University, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Progenics Pharmaceuticals
Other : JHU intellectual property rights
The SFI that result from the intellectual property rights is related in that its value could be affected by the research. Upon review by the institution, it was determined that Dr. Pomper’s SFI could directly and significantly affect the design, conduct or reporting of his research under this award.
High-Specificity Imaging Agents for Aggressive Prostate Cancer
The goals of this project are to leverage existing but untested agents and to develop new agents for imaging prostate cancer, with a focus on aggressive, localized disease. Identifying the most aggressive elements of a lesion within the prostate is critical for determining which patients should remain under active surveillance vs those who should undergo focal therapy or prostatectomy. We propose that that can best be done through imaging, and will do so through: (a) a pilot clinical trial using our recently described PET agent [18F] DCFPyL to identify intra-prostatic lesions; (b) synthesizing and testing a variety of new agents with improved binding affinity, pharmacokinetics and high specificity for aggressive disease; and (c) expanding from radionuclide techniques to MR imaging with signal amplification to leverage the clinical ubiquity of MR for managing prostate cancer.
Filed on June 14, 2018.
Tell us what you know about Martin Pomper's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Martin Pomper filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Martin Pomper | Johns Hopkins University | Conflict of Interest | Progenics Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.